How did HALO's revenue and expenses trend in Q4 2024?

Halozyme Therapeutics (HALO) demonstrated a consistent financial performance in Q4 2024, with stable revenue and controlled expenses, which contributed to a robust net income.

1. **Revenue Trend**: HALO's revenue for the quarter was $570.99 million. This figure indicates a strong revenue base, which is a positive indicator for the company's financial health and its ability to fund operations and invest in growth.

|code|Ticker|Name|Date|Business Composition|Revenue By Business|market_code|
|---|---|---|---|---|---|---|
|HALO|HALO.O|Halozyme Therapeutics|20240101-2024|Collaborative Agreements|1.40841E8|185|
|HALO|HALO.O|Halozyme Therapeutics|20240101-2024|Collaborative Agreements|9.2616E7|185|
|HALO|HALO.O|Halozyme Therapeutics|20240101-2024|Collaborative Agreements|4.4252E7|185|
|HALO|HALO.O|Halozyme Therapeutics|20240101-2024|Collaborative Agreements|1.6703E7|185|
|HALO|HALO.O|Halozyme Therapeutics|20240101-2024|Product|5.8583E7|185|
|HALO|HALO.O|Halozyme Therapeutics|20240101-2024|Royalties|1.20593E8|185|
|HALO|HALO.O|Halozyme Therapeutics|20240101-2024|Collaborative Agreements|1.6703E7|185|

|code|Ticker|Name|Date|Net Income YoY|Net Income|market_code|
|---|---|---|---|---|---|---|
|HALO|HALO.O|Halozyme Therapeutics|2024 Q1|93.92401867979301|7.6823E7|185|
|HALO|HALO.O|Halozyme Therapeutics|2024 Q2|24.735800090965032|9.3245E7|185|
|HALO|HALO.O|Halozyme Therapeutics|2024 Q3|67.41938243092977|1.37011E8|185|
|HALO|HALO.O|Halozyme Therapeutics|2024 Q4|60.458144001499036|1.37012E8|185|

|code|Ticker|Name|Date|Selling, General, and Administrative Expenses|Selling, General, and Administrative Expenses YoY|market_code|
|---|---|---|---|---|---|---|
|HALO|HALO.O|Halozyme Therapeutics|20240331|5.2897E7|-4.158211334976084|185|
|HALO|HALO.O|Halozyme Therapeutics|20240630|5.3473E7|-5.8292094464892665|185|
|HALO|HALO.O|Halozyme Therapeutics|20240930|5.9003E7|6.101420607804352|185|
|HALO|HALO.O|Halozyme Therapeutics|20241231|6.0011E7|8.381795195954487|185|

2. **Expense Management**: The company's operating expenses, research and development (R&D) expenses, and selling, general, and administrative (SG&A) expenses were $20.44 million, $60.01 million, and $60.01 million, respectively. The fact that these expenses are well-contained suggests that HALO has effective cost management practices in place, which is crucial for maintaining profitability.
3. **Net Income**: The net income for the quarter was $137.01 million. This figure, when compared to the revenue, indicates that HALO is not only generating substantial revenue but is also managing its expenses efficiently to convert revenue into net income.

In conclusion, HALO's financial performance in Q4 2024 was marked by strong revenue generation and effective expense management, which collectively contributed to a healthy net income. This trend is indicative of the company's solid financial foundation and its ability to invest in growth opportunities while maintaining profitability.